Allarity Therapeutics
ALLR
14 hedge funds and large institutions have $1.04M invested in Allarity Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.
2.27% less ownership
Funds ownership: 8.18% → 5.91% (-2.3%)
13% less funds holding
Funds holding: 16 → 14 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
26% less capital invested
Capital invested by funds: $1.4M → $1.04M (-$359K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.3K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$20.6K |
| 3 |
Citigroup
New York
|
+$8.36K |
| 4 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$1 |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$133K |
| 2 |
CAI
Capital Advisors Inc
Tulsa,
Oklahoma
|
-$108K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$91.4K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$60K |
| 5 |
Renaissance Technologies
New York
|
-$21K |
ALLR Hedge Fund Activity: Q1 2026 in Review
14 of the 8,169 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q1 2026, worth a combined $1.04M — down 26% from $1.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALLR and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, adding an estimated $36.3K. The largest seller was DRW Securities, exiting entirely with an estimated $133K sold.
- 14 institutional investors held Allarity Therapeutics (ALLR) as of Q1 2026, down from 16 in Q4 2025.
- Funds reported $1.04M of Allarity Therapeutics stock for Q1 2026, down 26% quarter-over-quarter.
- 5 funds opened new Allarity Therapeutics positions in Q1 2026 and 6 closed out, a net change of -1 holder.
- The largest Allarity Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $36.3K added.
- The largest Allarity Therapeutics seller in Q1 2026 was DRW Securities, an estimated $133K sold.
Based on aggregated 13F filings for Q1 2026.